Radiation sensitivity testing and late neurological complications following radiosurgery for AVM: The use of SF2 from fibroblasts as a predictive factor;Radiosensibilité et séquelles neurologiques tardives suite à la radiochirurgie de malformation artérioveineuse: La SF2 comme nouveau facteur prédictif

Cancer/Radiotherapie

Volumn 7, Issue 4, 2003, Pages 225-230

  Malone, S ^a   Szanto, J ^a   Alsbeith, G ^b   Szumacher, E ^a   Souhami, L ^c   Gray, R ^d   Girard, A ^a   Raaphorst, P ^a   Grimard, L ^a  

^a Centre Régional de Cancérologie d'Ottawa   (Canada)

^b Centre de Recherche   (Saudi Arabia)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Arteriovenous malformation; Radiation sensitivity; Radiosurgery; SF2

Indexed keywords

BIOLOGICAL FACTOR; RADIOSENSITIVITY SF2 FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTERIOVENOUS MALFORMATION; ARTICLE; CANADA; CLINICAL ARTICLE; DIAGNOSTIC VALUE; ELECTIVE SURGERY; FEMALE; FIBROBLAST CULTURE; HUMAN; IN VITRO STUDY; MALE; NEUROLOGIC DISEASE; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION NECROSIS; RADIOSENSITIVITY; RADIOSURGERY; SURGICAL RISK;

EID: 0041731738     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(03)00024-6     Document Type: Article

References (33)

1. Alsbeih G, Malone S, Lochrin C, Girard A, Fertil B, Raaphorst P. Correlation between normal tissue complications and in vitro radiosensitivity of skin fibroblasts derived from radiotherapy patients treated for variety of tumours. Int. J. Radiat. Oncol. Biol. Phys. 2000;Vol. 46(1):143-52.
2. Bernier J, Thames HD, Smith CD, Horiot JC. Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy. Radioth. Oncol. 1998;Vol. 47:137-43.
3. Brock WA, Tucker S, Geara F, Wike J, Peters L, Turesson I, Nyman J. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 1995;32(5):1371-9.
4. Burnet N, Nyman J, Turesson I, Wurm R, Yarnold J, Peacock J. The relationship between cellular radiation sensitivity and tissue response may provide the basis for individualizing radiotherapy schedules. Radiother. Oncol. 1994;Vol. 33:228-38.
5. Clarke RA, Goozee GR, Birrell G, Fang Z, Hasnain H, Lavin M, et al. Absence of ATM truncations in patients with severe acute radiation reactions. Int. J. Radiat. Oncol. Biol. Phys. 1998;Vol. 41:1021-7.
6. Coffey R, Nichols D, Shaw E. Stereotactic radiosurgical treatment of cerebral arteriovenous malformations. Mayo Clin Proc. 1995;70(3):214-22 [Gamma Unit Radiosurgery Study Group].
7. Colombo F, Pozza F, Chierego G, Casentini L, De Luca G, Francescon P. Linear accelerator radiosurgery for cerebral arteriovenous malformations. An update. Neurosurgery 1994;34(1):14-21.
8. Deacon J, Peckham M, Steel G. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother. Oncol. 1984;Vol 2:317-23.
9. Deschavanne P, Debieu D, Fertil B, Malaise E. Re-evaluation of in vitro radiosensitivity of human fibroblasts of different genetic origins. Int. J. Radiat. Oncol Biol. Phys. 1986;Vol 50:279-93.
10. Engenhart R, Wowra B, Debus J, Kimming B, Hover K, Lorenz W, et al. The role of high dose single-fraction irradiation in small and large intracranial arteriovenous malformations. Int. J. Radiat. Oncol. Biol. Phys. 1994;30(1):521-9.
11. Fertil B, Malaise EP. Inherent cellular radiosensitivity as a basic concept for human tumour radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1981;Vol. 7:621-9.
12. Flickenger J, Kondziolka D, Lundsford-Kassam A, Phuong L, Liscak R, et al. Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Int. J. Radiat. Oncol. Biol. Phys. 2000;Vol 46(No. 5):1143-8.
13. Flickinger JC, Kondziolka D, Maitz AH, Lunsford D. Analysis of neurological sequelae from radiosurgery of arteriovenous malformations: How location affects outcome. Int. J. Radiat. Oncol. Biol. Phys. 1998;Vol 40(no. 2):273-8.
14. Flickinger JC, Pollick BE, Kondziolka D, Lunsford D. A dose-response analysis of arteriovenous malformation obliteration after radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 1996;Vol. 36(No. 4):873-9.
15. Flickinger J, Schell M, Larson D. Estimation of complications for linear accelerator radiosurgery with the integrated logistic formula. Int. J. Radiat. Oncol. Biol. Phys. 1990;19:143-8.
16. Friedman W, Bova F. Linear accelerator radiosurgery for arteriovenous malformations. J. Neurosurg. 1992;77(6):832-41.
17. Friedman W, Bova F, Mendenhall W. Linear accelerator radiosurgery for arteriovenous malformations: The relationship of size to outcome. J. Neurosurg. 1995;82(2):180-9.
18. Geara FB, Peters LJ, Ang KK, Wike J, Brock W. Prospective comparison of in vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys. 1993;27:1173-9.
19. Johansen J, Bentzen SM, Overgaard J, Overgaard M. Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1994;66:407-12.
20. Johansen J, Bentzen SM, Overgaard J, Overgaard M. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangectasia, and skin erythema after radiotherapy. Radioth. Oncol. 1996;40:101-9.
21. Karlsson B, Lax I, Soderman M. Factors influencing the risk for complications following Gamma Knife radiosurgery of cerebral arteriovenous malformations. Radiotherapy and Oncology 1997;43:275-80.
22. Kjellberg R, Hanamura T, Davis J, Lyons S, Adams R. Bragg-peak proton-beam therapy for arteriovenous malformations of the brain. N. Engl. J. Med. 1983;309:269.
23. Kondziolka D, Lunsford L, Flickinger J. Gamma knife stereotactic radiosurgery for cerebral vascular malformation. In: Loeffler JL, Alexander III E, Lunsford L, editors. Stereotactic radiosurgery. New York: McGraw-Hill, Inc; 1993. p. 136-46.
24. Lindquist C, Steiner L. Stereotactic radiosurgical treatment of arteriovenous malformations. In: Lunsford LD, editor. Modern stereotactic neurosurgery. Boston: Martinus Nijhoff; 1988.
25. Loeffler J, Harris J, Dahlberg W, Little J. In vitro radiosensitivity of human diploid fibroblasts derived from women with unusually sensitive clinical responses to definitive radiation therapy for breast cancer. Radiat. Res. 1990;121:227-31.
26. Malone S, Raaphorst P, Gray R, Girard A, Alsbeith G. Enhanced in vitro radiosensitivity of skin fibroblasts in two patients developing brain necrosis following AVM radiosurgery: A new risk factor with potential for a predictive assay, Int. J. Radiat. Oncol. Biol. Phys. 2000;Vol. 47(No. 1):185-9.
27. Pollock B, Lunsford L, Kondziolka D, Maitz A, Flickinger J. Patient outcomes after stereotactic radiosurgery for "operable" arteriovenous malformations. Neurosurgery 1994;35(1):1-7.
28. Simomen P, Hamilton C, Ferguson S, Ostwald P, O'Brien M, O'Brien P, et al. Do inflammatory processes contribute to radiation induced erythema observed in the skin of humans? Radioth. Oncol. 1998;vol. 46:73-82.
29. Steinberg G, Fabrikant J, Marks M, Levy R, Frankel K, Phillips M, et al. Stereotactic radiosurgery for cerebral arteriovenous malformations. N. Engl. J. Med. 1990;323:96-101.
30. Steiner L, Leksell L, Greitz T, Forster D, Backlund E. Stereotactic radiosurgery for cerebral arteriovenous malformations. Acta Chir. Scand 1972;138:459-64.
31. Steiner L, Lindquist C, Adler J, Torner J, Alves W, Steiner M. Clinical outcome of radiosurgery for cerebral arteriovenous malformations. J. Neurosurg. 1992;77:1-8.
32. Turesson I. Individual variation and dose dependency in the progression rate of skin telangiectasia. Int. J. Radiat. Oncol. Biol. Phys. 1990;vol. 19:1569-74.
33. Turesson I, Nyman J, Holmberg E, Odén A. Prognostic factors for acute and late skin reactions in radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys. 1996;vol. 36:1065-75.